Annual Results Results Snapshot
Figures in Cr
Standalone Annual Results
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
Mar'20
Mar'19
Annual Analysis Highlights
Net Sales
YoY Growth in year ended Mar 2025 is 32.48% vs 29.17% in Mar 2024
Standalone Net Profit
YoY Growth in year ended Mar 2025 is -28.34% vs 62.66% in Mar 2024
Operating Profit (PBDIT) excl Other Income
YoY Growth in year ended Mar 2025 is 37.69% vs 11.71% in Mar 2024
Interest
YoY Growth in year ended Mar 2025 is 21.67% vs 90.48% in Mar 2024
Operating Profit Margin (Excl OI)
YoY Growth in year ended Mar 2025 has improved from Mar 2024
Compare Annual Results Of Astrazeneca Phar With
Figures in Cr
Standalone Annual Results
Change(INR)
Change(%)
Net Sales
1,716.29
2,281.35
-565.06
-24.77%
Other Operating Income
0.00
0.00
0.00
Total Operating income
1,716.29
2,281.35
-565.06
-24.77%
Raw Material Cost
287.13
272.34
14.79
5.43%
Purchase of Finished goods
1,008.82
512.75
496.07
96.75%
(Increase) / Decrease In Stocks
-332.94
25.36
-358.30
-1,412.85%
Employee Cost
257.44
371.33
-113.89
-30.67%
Power Cost
0.00
0.00
0.00
Manufacturing Expenses
0.00
0.00
0.00
Selling and Distribution Expenses
84.87
0.00
84.87
Other Expenses
157.00
359.34
-202.34
-56.31%
Total Expenditure (Excl Depreciation)
1,462.32
1,541.12
-78.80
-5.11%
Operating Profit (PBDIT) excl Other Income
253.97
740.23
-486.26
-65.69%
Other Income
40.63
172.25
-131.62
-76.41%
Operating Profit (PBDIT)
294.60
912.48
-617.88
-67.71%
Interest
1.46
8.41
-6.95
-82.64%
Exceptional Items
-96.79
172.81
-269.60
-156.01%
Gross Profit (PBDT)
196.35
1,076.88
-880.53
-81.77%
Depreciation
39.99
60.79
-20.80
-34.22%
Profit Before Tax
156.36
1,016.09
-859.73
-84.61%
Tax
40.62
248.49
-207.87
-83.65%
Provisions and contingencies
0.00
0.00
0.00
Profit After Tax
115.74
767.60
-651.86
-84.92%
Extraordinary Items
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
Net Profit
115.74
767.60
-651.86
-84.92%
Equity Capital
5.00
45.75
-40.75
-89.07%
Face Value
2.00
10.00
0.00
Reserves
765.35
4,171.66
-3,406.31
-81.65%
Earnings per share (EPS)
46.30
167.78
-121.48
-72.40%
Diluted Earnings per share
46.30
167.79
-121.49
-72.41%
Operating Profit Margin (Excl OI)
14.80%
32.45%
0.00
-17.65%
Gross Profit Margin
11.44%
47.20%
0.00
-35.76%
PAT Margin
6.74%
33.65%
0.00
-26.91%
Public Share Holdings (%)
0.00%
0.00%
0.00
0.00%
Pledged Promotor Holding (%)
0.00%
0.00%
0.00
0.00%
Annual - Net Sales
Net Sales 1,716.29 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is 32.48% vs 29.17% in Mar 2024
Annual - Standalone Net Profit
Standalone Net Profit 115.74 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is -28.34% vs 62.66% in Mar 2024
Annual - Operating Profit (PBDIT)
Operating Profit (PBDIT) 253.97 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is 37.69% vs 11.71% in Mar 2024
Annual - Interest
Interest 1.46 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is 21.67% vs 90.48% in Mar 2024
Annual - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 14.80%
in Mar 2025Figures in %
YoY Growth in year ended Mar 2025 has improved from Mar 2024
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
